Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhibition of Oral Tumorigenesis by Antitumor B
NCT04278989Phase 1Completed
- Sponsor
- Medical College of Wisconsin
- Start
- Apr 2022
- Primary completion
- May 2025
- Modality
- Botanical Extract
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Antitumor B in squamous cell carcinoma of the oral cavity (OSCC), sponsored by Medical College of Wisconsin. Primary endpoint: Percent of Ki-67 Positive Cells. Started Apr 2022; status: completed.
02
Drugs
Antitumor B
03
Conditions
squamous cell carcinoma of the oral cavity (OSCC)
Beyond the preview
Go deeper on NCT04278989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04278989.